Sign Out
As Kytril may reduce lower bowel motility, patients with signs of subacute intestinal obstruction should be monitored closely following administration of Kytril.
As with other 5-HT3 antagonists, cases of ECG modifications including QT prolongation have been reported with KYTRIL. These ECG changes with KYTRIL were minor and generally not of clinical significance, specifically with no evidence of proarrhythmia. However, in patients with pre-existing arrhythmias or cardiac conduction disorders, this might lead to clinical consequences. Therefore, caution should be exercised in patients with cardiac co-morbidities, on cardio-toxic chemotherapy and/or with concomitant electrolyte abnormalities.
Cross-sensitivity between 5-HT3 antagonists has been reported.
It is recommended that Kytril film-coated tablets are not taken by patients with rare hereditary problems of galactose intolerance, lactase deficiency or glucose-galactose malabsorption.
As with other 5-HT3 antagonists, cases of serotonin syndrome (including altered mental status, autonomic dysfunction and neuromuscular abnormalities) have been reported following the concomitant use of Kytril and other serotonergic drugs. If concomitant treatment with granisetron and other serotonergic drugs is clinically warranted, appropriate observation of this patient is advised.
Effects on Ability to Drive and Use Machines: In healthy subjects, no clinically relevant effects on resting EEG or on the performance of psychometric tests were observed after i.v. Kytril at any dose tested (up to 200 μg/kg). There are no data on the effect of Kytril on the ability to drive or use machinery.
